*Correspondence: Niklas Reich, [email protected] This article was submitted to Neurodegeneration, a section of the journal Frontiers in Neuroscience Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
The primary results from the SELECT trial, published almost two years ago, showed that high-dose semaglutide (the version approved as Wegovy for treating obesity) reduced peoples risk of heart attacks and other major cardiovascular events by 20% during the study period
Accessed April 5, 2026
AOD 9604 efficacy in clinical trials was modest at best
Led by Aloni Le, DNP, ARNP, FNP-C , a Board-Certified Nurse Practitioner with more than 13 years of advanced medical experience, our treatments are carefully designed to deliver what your body needs safely and effectively
Lifestyle intervention combined with pharmacotherapy outperforms either approach on its own